Cargando…
Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling
Platinum-based regimens have been routinely used in the clinical treatment of patients with esophageal squamous cell carcinoma (ESCC). However, administration of these drugs is frequently accompanied by drug resistance. Revealing the underlying mechanisms of the drug resistance and developing agents...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758349/ https://www.ncbi.nlm.nih.gov/pubmed/33363149 http://dx.doi.org/10.3389/fcell.2020.596788 |
_version_ | 1783626923296948224 |
---|---|
author | Cui, Wei Fang, Tingting Duan, Zhaoheng Xiang, Dongfang Wang, Yanxia Zhang, Mengsi Zhai, Fangzheng Cui, Xiang Yang, Lang |
author_facet | Cui, Wei Fang, Tingting Duan, Zhaoheng Xiang, Dongfang Wang, Yanxia Zhang, Mengsi Zhai, Fangzheng Cui, Xiang Yang, Lang |
author_sort | Cui, Wei |
collection | PubMed |
description | Platinum-based regimens have been routinely used in the clinical treatment of patients with esophageal squamous cell carcinoma (ESCC). However, administration of these drugs is frequently accompanied by drug resistance. Revealing the underlying mechanisms of the drug resistance and developing agents that enhance the sensitivity to platinum may provide new therapeutic strategies for the patients. In the present study, we found that the poor outcome of ESCC patients receiving platinum-based regimens was associated with co-expression of Shh and Sox2. The sensitivity of ESCC cell lines to cisplatin was related to their activity of Shh signaling. Manipulating of Shh expression markedly changed the sensitivity of ESCC cells to platinum. Continuous treatment with cisplatin resulted in the activation of Shh signaling and enhanced cancer stem cell-like phenotypes in ESCC cells. Dihydroartemisinin (DHA), a classic antimalarial drug, was identified as a novel inhibitor of Shh pathway. Treatment with DHA attenuated the cisplatin-induced activation of the Shh pathway in ESCC cells and synergized the inhibitory effect of cisplatin on proliferation, sphere and colony formation of ALDH-positive ESCC cells in vitro and growth of ESCC cell-derived xenograft tumors in vivo. Taken together, these results demonstrate that the Shh pathway is an important player in cisplatin-resistant ESCC and DHA acts as a promising therapeutic agent to sensitize ESCC to cisplatin treatment. |
format | Online Article Text |
id | pubmed-7758349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77583492020-12-25 Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling Cui, Wei Fang, Tingting Duan, Zhaoheng Xiang, Dongfang Wang, Yanxia Zhang, Mengsi Zhai, Fangzheng Cui, Xiang Yang, Lang Front Cell Dev Biol Cell and Developmental Biology Platinum-based regimens have been routinely used in the clinical treatment of patients with esophageal squamous cell carcinoma (ESCC). However, administration of these drugs is frequently accompanied by drug resistance. Revealing the underlying mechanisms of the drug resistance and developing agents that enhance the sensitivity to platinum may provide new therapeutic strategies for the patients. In the present study, we found that the poor outcome of ESCC patients receiving platinum-based regimens was associated with co-expression of Shh and Sox2. The sensitivity of ESCC cell lines to cisplatin was related to their activity of Shh signaling. Manipulating of Shh expression markedly changed the sensitivity of ESCC cells to platinum. Continuous treatment with cisplatin resulted in the activation of Shh signaling and enhanced cancer stem cell-like phenotypes in ESCC cells. Dihydroartemisinin (DHA), a classic antimalarial drug, was identified as a novel inhibitor of Shh pathway. Treatment with DHA attenuated the cisplatin-induced activation of the Shh pathway in ESCC cells and synergized the inhibitory effect of cisplatin on proliferation, sphere and colony formation of ALDH-positive ESCC cells in vitro and growth of ESCC cell-derived xenograft tumors in vivo. Taken together, these results demonstrate that the Shh pathway is an important player in cisplatin-resistant ESCC and DHA acts as a promising therapeutic agent to sensitize ESCC to cisplatin treatment. Frontiers Media S.A. 2020-12-10 /pmc/articles/PMC7758349/ /pubmed/33363149 http://dx.doi.org/10.3389/fcell.2020.596788 Text en Copyright © 2020 Cui, Fang, Duan, Xiang, Wang, Zhang, Zhai, Cui and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Cui, Wei Fang, Tingting Duan, Zhaoheng Xiang, Dongfang Wang, Yanxia Zhang, Mengsi Zhai, Fangzheng Cui, Xiang Yang, Lang Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title | Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title_full | Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title_fullStr | Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title_full_unstemmed | Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title_short | Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling |
title_sort | dihydroartemisinin sensitizes esophageal squamous cell carcinoma to cisplatin by inhibiting sonic hedgehog signaling |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758349/ https://www.ncbi.nlm.nih.gov/pubmed/33363149 http://dx.doi.org/10.3389/fcell.2020.596788 |
work_keys_str_mv | AT cuiwei dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT fangtingting dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT duanzhaoheng dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT xiangdongfang dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT wangyanxia dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT zhangmengsi dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT zhaifangzheng dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT cuixiang dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling AT yanglang dihydroartemisininsensitizesesophagealsquamouscellcarcinomatocisplatinbyinhibitingsonichedgehogsignaling |